Replies to post #253540 on Biotech Values

[Biowatch]

MRNA: FDA approves RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

https://finance.yahoo.com/news/moderna-receives-u-fda-approval-232500303.html

This might increase sales.

While the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable.1 Over one-third of adults aged 18-59 years have at least one underlying condition that puts them at increased risk of severe RSV disease,2 with disease burden and hospitalization rates in this population being comparable, or even exceeding, that observed in older adults.3

[DewDiligence]

MRNA 3Q25 mResvia sales=$2M, -80% YoY (not a typo):

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-reports-third-quarter-2025-financial-results-and-provides-bus-1097476